PE20211450A1 - Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4 - Google Patents

Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4

Info

Publication number
PE20211450A1
PE20211450A1 PE2020001409A PE2020001409A PE20211450A1 PE 20211450 A1 PE20211450 A1 PE 20211450A1 PE 2020001409 A PE2020001409 A PE 2020001409A PE 2020001409 A PE2020001409 A PE 2020001409A PE 20211450 A1 PE20211450 A1 PE 20211450A1
Authority
PE
Peru
Prior art keywords
yap1
oct4
interaction
inhibitors
directing
Prior art date
Application number
PE2020001409A
Other languages
English (en)
Inventor
Srikumar Chellappan
Nicholas J Lawrence
Sujeewa Ranatunga Mahanthe Mudiyanselage
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of PE20211450A1 publication Critical patent/PE20211450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referido a un compuesto de la formula I, en la que, la linea recortada representa un enlace que se encuentra presente o ausente; n es 0, 1 o 2; Ar es fenilo, piridinilo, pirimidinilo o pirazinilo; R1 es alquilo C1-C8, cicloalquilo C3-C6 o arilo C6, los cuales se encuentran opcionalmente sustituidos con uno o mas grupos seleccionados; R2 es halo, OH, alcoxilo C1-C8, entre otros; R3 es CH2OH, CO2H, CO2-C1-alquilo C6, entre otros; o una sal farmaceuticamente aceptable de estos. Estos compuestos son inhibidores de YAP1 que dirigen la interaccion de YAP1 con OCT4, evitando la autorrenovacion de celulas tipo madre de una poblacion lateral de lineas celulares tales como cancer de pulmon y mimetismo vascular. Tambien se refiere a metodos para producir dichos compuestos y su uso en el tratamiento del cancer.
PE2020001409A 2018-03-14 2019-03-14 Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4 PE20211450A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862643032P 2018-03-14 2018-03-14
PCT/US2019/022337 WO2019178401A1 (en) 2018-03-14 2019-03-14 Yap1 inhibitors that target the interaction of yap1 with oct4

Publications (1)

Publication Number Publication Date
PE20211450A1 true PE20211450A1 (es) 2021-08-05

Family

ID=67908080

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001409A PE20211450A1 (es) 2018-03-14 2019-03-14 Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4

Country Status (16)

Country Link
US (1) US11685725B2 (es)
EP (1) EP3765015A4 (es)
JP (1) JP2021515785A (es)
KR (1) KR20210006334A (es)
CN (1) CN111989100A (es)
AU (1) AU2019236196A1 (es)
BR (1) BR112020018642A2 (es)
CA (1) CA3093913A1 (es)
CL (1) CL2020002364A1 (es)
EA (1) EA202092174A1 (es)
IL (1) IL277314A (es)
MX (1) MX2020009519A (es)
PE (1) PE20211450A1 (es)
SG (1) SG11202008854TA (es)
WO (1) WO2019178401A1 (es)
ZA (1) ZA202005702B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111073858A (zh) * 2020-01-05 2020-04-28 浙江大学 一种yap1基因修饰的间充质干细胞及其制备方法
JPWO2023042901A1 (es) * 2021-09-16 2023-03-23

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
CA2359114A1 (en) 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
DK1539739T3 (da) 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
AR047537A1 (es) 2004-02-10 2006-01-25 Janssen Pharmaceutica Nv Piridazinonaureas como antagonistas de integrinas
WO2005121090A1 (en) * 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
WO2009044918A1 (ja) 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited ニューロメジンｕ誘導体
AR071377A1 (es) 2008-04-18 2010-06-16 Arete Therapeutics Inc Inhibidores de epoxido hidrolasa soluble
GB0807828D0 (en) 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102946882B (zh) 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2013188138A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
SG11201504633PA (en) 2012-12-19 2015-07-30 Novartis Ag Autotaxin inhibitors
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
EP3208280A4 (en) 2014-10-17 2018-10-10 Bao Kang Biomedical Healthcare Inc High activity tumour inhibitor and preparation method and use thereof
WO2018053446A1 (en) * 2016-09-18 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020009438A (es) 2018-03-14 2022-05-11 Kandy Therapeutics Ltd Formulacion farmaceutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3.

Also Published As

Publication number Publication date
IL277314A (en) 2020-10-29
MX2020009519A (es) 2020-10-22
KR20210006334A (ko) 2021-01-18
US20210363128A1 (en) 2021-11-25
SG11202008854TA (en) 2020-10-29
CA3093913A1 (en) 2019-09-19
US11685725B2 (en) 2023-06-27
ZA202005702B (en) 2022-04-28
CL2020002364A1 (es) 2021-01-29
WO2019178401A1 (en) 2019-09-19
BR112020018642A2 (pt) 2020-12-29
CN111989100A (zh) 2020-11-24
AU2019236196A1 (en) 2020-10-08
JP2021515785A (ja) 2021-06-24
EP3765015A1 (en) 2021-01-20
EP3765015A4 (en) 2021-12-15
EA202092174A1 (ru) 2021-01-15

Similar Documents

Publication Publication Date Title
CL2021000737A1 (es) Fabricación de compuestos y composiciones para inhibir la actividad de shp2
PE20160044A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
PE20150128A1 (es) Moduladores del transporte nuclear y usos de los mismos
PE20170206A1 (es) Inhibidores espirociclicos sustituidos de la autotaxina
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
PE20211450A1 (es) Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4
AR097325A1 (es) Pirroles anillados
AR116283A1 (es) Inhibidores del sarcómero cardíaco
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR091490A1 (es) Antagonistas de iap
AR084144A1 (es) Compuestos y metodos para restaurar la piel
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
AR118729A1 (es) Inhibidor selectivo de la jak1 quinasa
PE20190119A1 (es) Esteres de oxaborol y sus usos
AR115768A1 (es) Inhibidores bicíclicos de las histona desacetilasas